SeeThruEquity starts Cynata Therapeutics with target price of A$1.55

3 September 2015
2019_biotech_test_vial_discovery_big

SeeThruEquity Research initiated coverage on Australia-based biotechnology company Cynata Therapeutics (ASX: CYP) with a target price of A$1.55.

For the full-year 2016 the broker expects revenue of A$5 million ($3.6 million) with pretax profit of A$1.6 million. Outlook for net income stands at A$1.6 million with earnings per share of A$0.02.

Headquartered in Melbourne, Cynata is engaged in developing a therapeutic stem cell platform. The company does not have any products in the market so far.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology